CRS occurred in 18 patients (78.3%) during CD19 CAR-T cell therapy, including seven (30.4%) with grade 1, nine (39.1%) with grade 2, and two (8.7%) with grade 3 CRS. This evidence concerns the gene CD19 and congenital rubella syndrome.